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Mesenchymal stem cells (MSCs) may cure life-threatening
acute GVHD, but long-term survival has been unsatisfactory.
The placenta protects the fetus from the mother’s immune
system, and placental tissues have been used for over 100
years in Africa to successfully treat burn injuries. Decidual
stromal cells (DSCs) are accessible without any invasive
procedure, with little or no need for ethical considerations,
as the placenta is normally discarded after delivery. We
isolate, culture, expand, and store DSCs from term placentas.
They have fundamental differences to MSCs. DSCs do not
differentiate as well to bone or cartilage. DSCs need cell-to-
cell contact to be immunosuppressive and to induce FoxP3
regulatory T-cells. Blocking of the activity of IDO, prosta-
glandin E2, PD-L1, and interferon impairs the immunosup-
pressive capacity of DSCs inMLC. Human DSCs inhibit MLC in
mice. MCSs and DSCs induce xenoreactivity.
In culture, DSCs can be expanded appreciably, and from
one placenta we can obtain enough cells to treat more than
20 patients.With early treatment (withinmedian six days) of
steroid refractory acute GVHD, one-year survival was 73%d
as opposed to 6% in retrospective controls not treated with
stromal cells (p<0.001). A partial responsewas seen in two of
three patients with severe chronic GVHD. Twelve patients
have been treated for hemorrhagic cystitis, and nowwe have
proceeded with a prospective double-blind randomized
study. A 33-year-old man developed acute respiratory
distress syndrome (ARDS) after septicemia and ASCT. He
required 15 L/min oxygen by mask. After infusion of 1  106
DSCs, oxygen saturation increased instantly from 92% to 98%;
requirement for oxygen decreased, and it was discontinued
after ﬁve days. Chest radiography improved and elevations in
cytokines/chemokines, G-CSF, IL-6, IL-8, MCP-1, and TNF-alfa
decreased. The patient is now alive and well eight months
after ASCT. We reversed paresis in the arms and legs
(respectively) of two patients with polyneuropathies. The
ﬁrst patient had recurrence of paresis and needed two
additional infusions of DSCs. The second patient has no
symptoms four months after infusion. Altogether, we have
treated 59 patients with 136 doses of DSCs and we have not
seen any acute side effects.
To conclude, DSCs are an effective therapy for acute and
chronic GVHD, hemorrhagic cystitis, ARDS, and neuropathy.
So far, we have not seen any side effects.
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Although autologous or donor-derived EBV-speciﬁc T cells
(EBVSTs) have remarkable clinical efﬁcacy for Hodgkin and
non-Hodgkin lymphoma, the lengthy manufacturing process
and anergy of patient tumor-speciﬁc T cells reduce the
feasibility of widespread use. An alternative approach is
establishment of a pre-made third party bank that can pro-
vide access to VSTs for almost any patient. We previously
evaluated multivirus-speciﬁc third-party T cells for re-
fractory viral infections after HSCT. Of 50 recipients, 74%
responded, even when T cells were HLA-matched at only a
single allele. Although established banks consist primarily of
donors from national marrow registries or family members
according to HLA genotype, there aremany limitations to this
approach, including the generation of lines with limited
speciﬁcity for the targeted antigens. To circumvent these
drawbacks, we have developed a strategic approach to
generating third-party lines for treatment of EBV+ lym-
phoma. Our bank has been generated from blood-bank
eligible donors, initially chosen based on racial diversity thus
predicted to have HLA haplotypes representative of our
diverse patient population. Donors were subsequently
screened for speciﬁcity to the EBV Type 2 latency antigens
(LMP1/2, EBNA1, and BARF1) with IFN-g Elispot assays using
overlapping peptide libraries (pepmixes) spanning each an-
tigen. The EBVSTs exhibited signiﬁcant speciﬁcity (with
>50% of donors recognizing 3 of the 4 antigens) and cyto-
toxicity to both pepmix-pulsed autologous activated T cells
(ATCs) and HLA-matched EBV-lymphoblastoid cell lines
(LCLs) that naturally express viral antigens. To ensure that
the best EBVST line is chosen for each recipient, it is impor-
tant to ensure antigen-speciﬁc activity restricted by the al-
leles shared between donor and recipient. To characterize
HLA restrictionwe use peptides or pepmix-pulsed PHA blasts
or LCLs that are HLA matched at a single class I or II allele as
target cells in cytotoxicity assays. We then constructed a
database in which the HLA restriction of the antigen speci-
ﬁcity of each T cell line is listed. Based on data from our third
party trivirus-speciﬁc T cell study, we expect that our pro-
jected bank of 30 highly characterized EBVSTs will cover
>95% of referred patients (with matching at  2 class I and/
or class II alleles) since our screening strategy ensures that a
wide range of HLA haplotypes is covered. Additionally, given
the signiﬁcantly increased virus speciﬁcity of our highly
characterized donors, we expect to see signiﬁcant anti-tu-
mor activity. This study will therefore allow us to determine
whether third-party T cells can be effective outside the HSCT
setting in patients who are not immunocompromised.176
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Abstracts / Biol Blood Marrow Transplant 21 (2015) S147eS170S150Allogeneic hematopoietic stem cell transplantation (HSCT) is
commonly used as a treatment for hematological malig-
nancies, immunodeﬁciencies, and inborn errors of me-
tabolism. HSCT is associated with several complications and
risk factors, for example graft-versus-host disease (GVHD),
viral infections, relapse, and graft rejection. Infusions of extra
lymphocytes from the original stem cell donor can be used as
a treatment after transplantation for, e.g., relapse, poor im-
mune reconstitution or secondary graft failure. The term
booster applies for infusions of donor cells without condi-
tioning. Secondary graft failure was in this study deﬁned as
initial signs of engraftment with subsequent development of
bone marrow hyperplasia requiring frequent transfusions
beyond day 60 as well as prolonged neutropenia and
thrombocytopenia. While high levels of CD3+ cells in grafts
can increase the risk for GVHD they can also promote the
graft versus leukemia (GVL) effect. In peripheral blood, 95% of
T-cells express the ab T-cell receptor and the remaining T-
cells express the gd T-cell receptor, which are not dependent
upon human leukocyte antigen (HLA) molecules for activa-
tion. As ab T-cells are the primary mediators of GVHD,
depleting them from the graft should reduce this risk, leav-
ing gd T-cells as primary Tecell type in the booster infusion.
In this pilot study, ﬁve patients transplanted with HLA-
matched related and unrelated donors were treated with ab
T-cell depleted stem cell boosts, with secondary graft failure
as primary indication. All patients also suffered from infec-
tious complications prior to the infusion, which is likely to
have been associated with the poor graft function and
development of secondary graft failure. The ab T-cell deple-
tion was performed using a CliniMACS system (Miltenyi
Biotech). Analysis of the booster infusion fraction as well as
blood samples from the patients was performed; cell char-
acterization by using ﬂow cytometry and evaluation of
chimerism as well spectratyping of gd-chains by using PCR.
Monitoring of white blood cells, platelets, and granulocytes
was carried out for 30 days post infusion. The majority of gd
T-cells in the grafts expressed Vd2 and/or Vd9. Median log
depletion of gd T-cells in the products was 3.72, and the
mean yield of gd Tecells was 84.4%. Most patients receiving
ab-depleted stem cell boosts increased their levels of white
blood cells, platelets, and/or granulocytes 30 days post
infusion. No signs of GVHD or other side effects were
detected. A larger pool of patients with longer follow-up time
is needed to conﬁrm the data in this study and compare the
treatment modality to other therapy options.177
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A major caveat of FOXP3+ T regulatory cells in immuno-
therapy against GVHD is their lownumbers in circulation and
the lack of speciﬁc cell surface markers for efﬁcient puriﬁ-
cation. DNA methylation plays a key role in the regulation of
T-cell effector function and cytokine gene expression,indicating a promising role of hypomethylating agents in
immunomodulation. Recently it was shown that in vitro
treatment of conventional T-cells with the hypomethylating
agent azacitidine (aza) induced FoxP3 expression and con-
verted CD4+CD25- cells into immunosuppressive T-cells, the
suppressor function of which is independent of FoxP3
expression (Blood 2010;116:129-139), suggesting that aza
induced suppressor function depends on the modiﬁcation of
other hypomethylated genes. Human leukocyte antigen-G
(HLA-G) is a non-classical HLA class I molecule, shown to
exert immunoregulatory functions, the expression of which
is epigenetically regulated. In this study we investigated
whether hypomethylating agents (HAs) can induce HLA-G+
immunoregulatory T cells. Negative selected T cells from
peripheral blood of healthy individuals were stimulated with
anti-CD3 plus anti-CD28 coated beads, then treated for 72
hours with aza (0.5-15 mM) in the presence of 50U/ml
inteleukin-2 (IL-2). Phenotypical characterization of aza
treated cells was performed with ﬂow cytometry. The effect
of HAs on HLA-G mRNA transcription and methylation of
upstream regulatory HLA-G gene DNA sequence was quan-
titated with Real time PCR and bisulﬁte pyrosequencing
respectively. Hypomethylation-induced HLA-G+ T cells, were
irradiated and then used as third party cells in suppression
assays. In vitro treatment of CD3+ T cells with aza induces,
dose dependent, de-novo HLA-G expression on stimulated
peripheral T cells of healthy individuals. The optimum aza
concentration for maximum HLA-G induction with the
lowest toxicity in CD3 T cells was determined at 5 mM
(surface expressing HLA-G cells: 6,883,9%, p¼0,0022, fold
increase in HLA-G mRNA relevant expression: 18,322,33).
Methylation analysis of 13CpGs revealed that treatment with
HAs caused hypomethylation of the HLA-G upstream-regu-
latory region followed by mRNA transcription and up-regu-
lation of surface protein expression. Stability assays revealed
that HLA-G expression is evident for at least 3 days after
removal of hypomethylating agent. In vitro Aza induced HLA-
G+ cells are immunosuppressive and HLA-G blocking exper-
iments further conﬁrmed that their suppressive function is
largely but not exclusively dependent on HLA-G. Phenotypic
analysis revealed that aza induced CD4+HLA-G+ are FoxP3
negative CD4lowCD25high. Conclusively, by using hypo-
methylating agent aza in vitro, we generated a CD4low-
FoxP3neg immunoregulatory population, which expresses
extracellular HLA-G and therefore can be easily isolated for
adaptive immunotherapies.178
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Novel therapeutic approaches are urgently needed for many
malignancies such as Acute Myeloid Leukemia (AML). We
have developed a new therapeutic strategy based upon NK
cell immunotherapy that exhibits high clinical potential
based upon cell and animal studies. While the harnessing of
NK cells for cellular therapy against malignancies has been a
topic of interest for several decades, our approach overcomes
a major hurdle of insufﬁcient NK cell cytotoxic activity. We
have identiﬁed that targeting the kinase GSK3 through
pharmacologic and genetic approaches leads to the hyper-
activation of human blood derived NK cells and a signiﬁcant
